Sugi Predict

Sugi Predict / Compounds / SCHEMBL4658586

SCHEMBL4658586

SCHEMBL4658586

Fc1ccc(NBr)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.46
▸ ALDH1A1 P00352 4/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ THRB P10828 1/20 0.42
▸ SOS1 Q07889 1/20 0.42
▸ GAA P10253 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27614646 0.80 CA3 (0.42) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL19112710 0.76 HTT (0.47) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL29669311 0.76 KMT2A (0.47) HTTNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL10003657 0.76 CYP1A2 (0.34) HTTNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL8064140 0.76 ALDH1A1 (0.44) HTTALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL182042 0.75 CA1 (0.53) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18500606 0.75 HTT (0.46) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL29471763 0.75 CA1 (0.53) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1777530 0.75 HTT (0.46) HTTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27669063 0.75 HTT (0.46) HTTALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102558241-B Preparation of 1,10-phenanthroline complex substituted by propionyl group and application of complex used as catalyst CHINA PETROLEUM & CHEMICAL 2014-11-26 — — CN claimed
CN-102532201-B Preparation of formoxyl substitutional 1, 10-phenanthroline coordination compound and application of prepared coordination compound as catalyst CHINA PETROLEUM & CHEMICAL 2014-11-05 — — CN claimed
CN-102558242-B Preparation of isobutyryl substituted 1,10-phenanthroline complex and application of complex serving as catalyst SINOPEC CORP. (CN) 2014-10-22 — — CN claimed
CN-102558243-B Preparation method of alkyl-substituted 1,10-phenanthroline complex and application of complex prepared thereby as catalyst SINOPEC CORP. (CN) 2014-10-22 — — CN claimed
CN-103804428-A Preparation method and application of complex CHINA PETROLEUM & CHEMICAL 2014-05-21 — — CN claimed
EP-4455116-A1 PROCESS FOR THE PREPARATION OF HALODIFLUOROBENZENE Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
CN-116096710-A 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders 阿雷生物药品公司 2023-05-09 — — CN disclosed
CN-110003170-A Carboxylic acid ester compounds and their use as herbicides 美国陶氏益农公司 2019-07-12 — — CN disclosed
CN-103328516-B Activated carrier 英尼奥斯欧洲股份公司 2019-06-28 — — CN disclosed
CN-109715612-A SOMATOSTATIN MODULATORS AND USES THEREOF 克林提克斯医药股份有限公司 2019-05-03 — — CN disclosed
CN-109641868-A Inhibitors of influenza viruses replication and its application method and purposes 广东东阳光药业有限公司 2019-04-16 — — CN disclosed
CN-108727369-A Inhibitors of influenza viruses replication and application thereof 广东东阳光药业有限公司 2018-11-02 — — CN disclosed
US-20070185152-A1 Inhibitors of akt activity SMITHKLINE BEECHAM CORPORATION 2007-08-09 — — US disclosed
EP-1556351-A4 SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF LUNDBECK & CO AS H (DK) 2007-07-25 — — EP disclosed
EP-1720855-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 — — EP disclosed
WO-2005085227-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-09-15 — — WO disclosed
EP-1556351-A1 SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF H. Lundbeck A/S (DK) 2005-07-27 — — EP disclosed
WO-2004005257-A1 SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF H. LUNDBECK A/S (DK) 2004-01-15 — — WO disclosed
EP-1206440-A1 METHOD FOR MONOHALOGENATING AMINOAROMATIC DERIVATIVES RHODIA CHIMIE (FR) 2002-05-22 — — EP disclosed
WO-2001014311-A1 METHOD FOR MONOHALOGENATING AMINOAROMATIC DERIVATIVES RHODIA CHIMIE (FR) 2001-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185152-A1 Inhibitors of akt activity AKT1, AKT1S1, AKT2 HTT 1788/4885ALDH1A1 4421/4885NPC1 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.